Is SCHD a Good ETF to Buy?
With around $65.7 billion in net assets, Schwab’s US Dividend…
Buy
61
ZOM Quote, Financials, Valuation and Earnings
Last price:
$0.14
Seasonality move
:
59.56%
Day range:
$0.14 - $0.15
52-week range:
$0.12 - $0.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.18x
P/B ratio:
0.68x
Volume:
8.2M
Avg. volume:
7.1M
1-year change:
-20.97%
Market cap:
$138.5M
Revenue:
$25.2M
EPS (TTM):
-$0.07
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Zomedica has 76.93% upside to fair value with a price target of -- per share.
ZOM vs. S&P 500
-
Over the past 5 trading days, Zomedica has overperformed the S&P 500 by 15.98% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Zomedica does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Zomedica has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Zomedica reported revenues of $7M.
Earnings Growth
-
Zomedica has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Zomedica reported earnings per share of -$0.01.
Enterprise value:
61.6M
EV / Invested capital:
--
Price / LTM sales:
5.18x
EV / EBIT:
--
EV / Revenue:
2.30x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-3.07x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$18.6M
Return On Assets:
-25.79%
Net Income Margin (TTM):
-232.7%
Return On Equity:
-27.17%
Return On Invested Capital:
-27.17%
Operating Margin:
-106.33%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $16.9M | $24M | $26.7M | $6.3M | $7M | |
| Gross Profit | $12.3M | $16.5M | $18.6M | $4.4M | $5.1M | |
| Operating Income | -$22.6M | -$25.3M | -$38.3M | -$5.9M | -$7.4M | |
| EBITDA | -$17M | -$11.9M | -$54.3M | -$751K | -$4.7M | |
| Diluted EPS | -$0.01 | -$0.02 | -$0.07 | -$0.00 | -$0.01 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $53.1M | $274.7M | $127.1M | $115.4M | $87.3M | |
| Total Assets | $56.6M | $277.5M | $282.3M | $275.1M | $214.1M | |
| Current Liabilities | $2.1M | $4.9M | $7.1M | $6.7M | $8.1M | |
| Total Liabilities | $3.2M | $5.9M | $13.5M | $14.2M | $11.3M | |
| Total Equity | $53.4M | $271.6M | $268.8M | $260.9M | $202.8M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$14.2M | -$13.3M | -$24.1M | -$3M | -$4.8M | |
| Cash From Investing | -$212.1M | -$9.9M | $12.1M | -$3.1M | $6.5M | |
| Cash From Financing | -- | -- | -- | -- | -$70K | |
| Free Cash Flow | -$16.4M | -$25.8M | -$20.1M | -$9.6M | -$5.9M | |
ZOM
Sector
Market Cap
$138.5M
$49.2M
Price % of 52-Week High
72.39%
48.64%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-20.97%
-30.44%
Beta (5-Year)
1.069
0.754
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$0.13
200-day SMA
Sell
Level
$0.14
Bollinger Bands (100)
Buy
Level
0.12 - 0.14
Chaikin Money Flow
Sell
Level
-1B
20-day SMA
Buy
Level
$0.13
Relative Strength Index (RSI14)
Buy
Level
64.96
ADX Line
Buy
Level
44.51
Williams %R
Neutral
Level
-41.75
50-day SMA
Buy
Level
$0.13
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Buy
Level
40
On Balance Volume
Neutral
Level
3.9B
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (8.0509)
Buy
CA Score
(Annual)
Level (1.0442)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (2.1723)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its operations are comprised of two reportable segments namely Diagnostic and Therapeutic Devices. It earns the majority of revenue from the therapeutics segment.
Stock Forecast FAQ
In the current month, ZOM has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ZOM average analyst price target in the past 3 months is --.
-
Where Will Zomedica Stock Be In 1 Year?
According to analysts, the consensus estimate is that Zomedica share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Zomedica?
Analysts are divided on their view about Zomedica share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Zomedica is a Sell and believe this share price will drop from its current level to --.
-
What Is Zomedica's Price Target?
The price target for Zomedica over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ZOM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Zomedica is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of ZOM?
You can purchase shares of Zomedica via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Zomedica shares.
-
What Is The Zomedica Share Price Today?
Zomedica was last trading at $0.14 per share. This represents the most recent stock quote for Zomedica. Yesterday, Zomedica closed at $0.14 per share.
-
How To Buy Zomedica Stock Online?
In order to purchase Zomedica stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is NAIL a Good ETF to Buy?
If you’re thinking about buying the NAIL ETF, this article…
3 High Dividend Dow Jones Stocks
Thanks to surging stock prices over the past two years,…
Stock Ideas
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Sell
43
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Buy
57
NARI alert for Jan 8
Inari Medical [NARI] is up 0.15% over the past day.
Buy
69
UNF alert for Jan 8
UniFirst [UNF] is up 2.27% over the past day.
Sell
31
APOG alert for Jan 8
Apogee Enterprises [APOG] is down 6.23% over the past day.
